Mumbai: Sun Pharmaceutical Industries on Monday
said it has settled its dispute with US-based pharma firm
MedImmune for marketing a generic version of latter's Ethyol,
a drug used in the treatment of head and neck cancer.
The company, along with its subsidiaries, has "executed a
settlement agreement with MedImmune, stipulating the dismissal
of the lawsuits" filed in the US District Court of Maryland
regarding generic version of Ethyol, drug maker Sun Pharma
said in a filing to the Bombay Stock Exchange (BSE).
Under the settlement agreement, MedImmune would grant a
licence to Sun Pharma for certain patents, permitting the
India-headquartered company to continue marketing the generic
version of Ethyol in the US, it further said.
"The settlement resolves the entirety of the litigation
between the parties," Sun Pharma said. The terms of settlement
are confidential.
Ethyol is a prescription drug given through injection
prior to each postoperative radiation treatment session for
head and neck cancer. It is used to lower the rate of moderate
to severe xerostomia (dry mouth).
Shares of Sun Pharma were trading at Rs 1,164.20, down
0.66 percent in afternoon trade on the BSE.
Bureau Report
First Published: Monday, August 03, 2009, 13:52